0000899243-21-021651.txt : 20210602
0000899243-21-021651.hdr.sgml : 20210602
20210602200215
ACCESSION NUMBER: 0000899243-21-021651
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210601
FILED AS OF DATE: 20210602
DATE AS OF CHANGE: 20210602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith-Whitley Kim
CENTRAL INDEX KEY: 0001860297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 21990867
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 181 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001860297
Smith-Whitley Kim
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Restricted Stock Units
2021-06-01
4
A
0
24160
0.00
A
Common Stock
24160
24160
D
Restricted Stock Units
2021-06-01
4
A
0
6300
0.00
A
Common Stock
6300
6300
D
Stock Option (Right to Buy)
37.20
2021-06-01
4
A
0
35500
0.00
A
2031-05-31
Common Stock
35500
35500
D
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
The RSUs vest with respect to 25% of the underlying shares on June 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The stock option vests with respect to 25% of the underlying shares on May 3, 2022 and in 12 equal quarterly installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Title: EVP, Head of Research & Development
/s/ Tricia Suvari , Attorney-in-Fact
2021-06-02